JP2021504384A - Ｌｓｚ１０２及びアルペリシブを含む医薬品の組合せ - Google Patents

Ｌｓｚ１０２及びアルペリシブを含む医薬品の組合せ Download PDF

Info

Publication number
JP2021504384A
JP2021504384A JP2020529159A JP2020529159A JP2021504384A JP 2021504384 A JP2021504384 A JP 2021504384A JP 2020529159 A JP2020529159 A JP 2020529159A JP 2020529159 A JP2020529159 A JP 2020529159A JP 2021504384 A JP2021504384 A JP 2021504384A
Authority
JP
Japan
Prior art keywords
combination
lsz102
day
amide
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020529159A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021504384A5 (enExample
Inventor
アブラムス，ティニア
アレクサンダー ガイサー，ラリー
アレクサンダー ガイサー，ラリー
Original Assignee
ノバルティス アーゲー
ノバルティス アーゲー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ノバルティス アーゲー, ノバルティス アーゲー filed Critical ノバルティス アーゲー
Publication of JP2021504384A publication Critical patent/JP2021504384A/ja
Publication of JP2021504384A5 publication Critical patent/JP2021504384A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2020529159A 2017-12-01 2018-11-29 Ｌｓｚ１０２及びアルペリシブを含む医薬品の組合せ Pending JP2021504384A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762593760P 2017-12-01 2017-12-01
US62/593,760 2017-12-01
US201862771757P 2018-11-27 2018-11-27
US62/771,757 2018-11-27
PCT/IB2018/059470 WO2019106604A1 (en) 2017-12-01 2018-11-29 Pharmaceutical combination comprising lsz102 and alpelisib

Publications (2)

Publication Number Publication Date
JP2021504384A true JP2021504384A (ja) 2021-02-15
JP2021504384A5 JP2021504384A5 (enExample) 2022-01-06

Family

ID=64901034

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020529159A Pending JP2021504384A (ja) 2017-12-01 2018-11-29 Ｌｓｚ１０２及びアルペリシブを含む医薬品の組合せ

Country Status (6)

Country Link
US (2) US10695333B2 (enExample)
EP (1) EP3716969A1 (enExample)
JP (1) JP2021504384A (enExample)
CN (1) CN111386113A (enExample)
TW (1) TW201924675A (enExample)
WO (1) WO2019106604A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023516951A (ja) * 2020-02-27 2023-04-21 サノフイ アルペリシブおよび６－（２，４－ジクロロフェニル）－５－［４－［（３ｓ）－１－（３－フルオロプロピル）ピロリジン－３－イル］オキシフェニル］－８，９－ジヒドロ－７ｈ－ベンゾ［７］アヌレン－２－カルボン酸を含む組合せ物

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019097426A1 (en) 2017-11-16 2019-05-23 Novartis Ag Pharmaceutical combination comprising lsz102 and ribociclib
TW202026280A (zh) 2018-09-07 2020-07-16 法商賽諾菲公司 6-(2,4-二氯苯基)-5-[4-[(3s)-1-(3-氟丙基)吡咯啶-3-基]氧基苯基]-8,9-二氫-7h-苯並[7]輪烯-2-甲酸甲酯的鹽及其製備方法
EP3849545A1 (en) * 2018-09-10 2021-07-21 Institut National de la Santé et de la Recherche Médicale (INSERM) Methods for the treatment of neurofibromatosis

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016509022A (ja) * 2013-02-19 2016-03-24 ノバルティス アーゲー 選択的エストロゲン受容体ディグレーダーとしてのベンゾチオフェン誘導体およびその組成物
WO2017077445A1 (en) * 2015-11-02 2017-05-11 Novartis Ag Dosage regimen for a phosphatidylinositol 3-kinase inhibitor

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2008003189A (es) 2005-09-07 2008-03-18 Serono Lab Inhibidores de fosfoinositido 3-cinasa para el tratamiento de endometriosis.
UA104147C2 (uk) 2008-09-10 2014-01-10 Новартис Аг Похідна піролідиндикарбонової кислоти та її застосування у лікуванні проліферативних захворювань
EP2650401A1 (de) 2012-04-10 2013-10-16 Siemens Aktiengesellschaft Kraftwerk basiertes Methanisierungssystem
EA031077B1 (ru) * 2013-06-19 2018-11-30 Серагон Фармасьютикалз, Инк. Модулятор рецептора эстрогена и его применения
ES2900829T3 (es) 2013-08-14 2022-03-18 Novartis Ag Terapia combinada para el tratamiento del cáncer
WO2015028409A1 (de) 2013-08-27 2015-03-05 Bayer Pharma Aktiengesellschaft 6,7-dihydro-5h-benzo[7]annulen-derivate, verfahren zu ihrer herstellung, pharmazeutische präparate die diese enthalten, sowie deren verwendung zur herstellung von arzneimitteln
JP6223154B2 (ja) 2013-11-29 2017-11-01 ロッテ アドバンスト マテリアルズ カンパニー リミテッド ポリアミド樹脂およびその製造方法
SG11201607334YA (en) 2014-03-13 2016-10-28 Hoffmann La Roche Therapeutic combinations with estrogen receptor modulators
WO2016176665A1 (en) 2015-04-29 2016-11-03 Radius Health, Inc. Methods of treating cancer
AU2016287189A1 (en) * 2015-06-29 2017-10-12 F. Hoffmann-La Roche Ag Methods of treatment with taselisib
JP7084875B2 (ja) * 2016-03-29 2022-06-15 ノバルティス アーゲー 水－界面活性剤混合物を含む反応媒体
AU2018205262A1 (en) 2017-01-06 2019-07-11 G1 Therapeutics, Inc. Combination therapy for the treatment of cancer
WO2019097426A1 (en) * 2017-11-16 2019-05-23 Novartis Ag Pharmaceutical combination comprising lsz102 and ribociclib

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016509022A (ja) * 2013-02-19 2016-03-24 ノバルティス アーゲー 選択的エストロゲン受容体ディグレーダーとしてのベンゾチオフェン誘導体およびその組成物
WO2017077445A1 (en) * 2015-11-02 2017-05-11 Novartis Ag Dosage regimen for a phosphatidylinositol 3-kinase inhibitor

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
樋口智子、三好康雄: "分子標的薬の治療標的と作用メカニズム", 日本内分泌・甲状腺外科学会雑誌, vol. 第32巻 第2号, JPN6023006750, 2015, pages 74 - 79, ISSN: 0004995578 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023516951A (ja) * 2020-02-27 2023-04-21 サノフイ アルペリシブおよび６－（２，４－ジクロロフェニル）－５－［４－［（３ｓ）－１－（３－フルオロプロピル）ピロリジン－３－イル］オキシフェニル］－８，９－ジヒドロ－７ｈ－ベンゾ［７］アヌレン－２－カルボン酸を含む組合せ物

Also Published As

Publication number Publication date
US20210000810A1 (en) 2021-01-07
CN111386113A (zh) 2020-07-07
WO2019106604A1 (en) 2019-06-06
US20190167652A1 (en) 2019-06-06
US10695333B2 (en) 2020-06-30
TW201924675A (zh) 2019-07-01
EP3716969A1 (en) 2020-10-07

Similar Documents

Publication Publication Date Title
EP2739153B1 (en) Treatment of breast cancer
JP2022519375A (ja) Ｔｎｏ１５５及びリボシクリブを含む医薬組合せ
TWI607754B (zh) 醫藥組合
US20210000810A1 (en) Pharmaceutical combination comprising lsz102 and alpelisib
KR20190021355A (ko) Ar+ 유방암 치료 방법
EP3890834A1 (en) Methods for treating cancer resistant to cdk4/6 inhibitors
EP4119557A1 (en) Pharmaceutical combination comprising pyridino[1,2-a]pyrimidinone compound
KR102517650B1 (ko) 유방암의 치료를 위한 조합물 요법
CN114246864B (zh) Csf1r激酶抑制剂及其用途
JP2016520662A (ja) Ｐｉ３ｋ阻害剤および微小管不安定化剤の医薬組み合わせ
JP2021503448A (ja) Ｌｓｚ１０２及びリボシクリブを含む医薬組合せ
JP2025535154A (ja) 癌を治療するためのｓｅｒｄの併用
JPWO2004035089A1 (ja) ホルモン依存性癌の治療剤
KR20240170957A (ko) 암 치료를 위한 병용 요법
US20250170146A1 (en) Niraparib and abiraterone acetate plus prednisone to improve clinical outcomes in patients with metastatic castration-resistant prostate cancer and hrr alterations
EP4504180A1 (en) Combination therapy for treating cancer
TW202440096A (zh) 雌激素受體降解劑之給藥方案
AU2023250030A1 (en) Combination therapy for treating cancer
CN118632695A (zh) 尼拉帕尼和醋酸阿比特龙加泼尼松用于改善患有转移性去势抵抗性前列腺癌和hrr改变的患者的临床结果
HK1198867B (en) Treatment of breast cancer

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211129

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20211129

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20220922

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230221

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20230926